DSCA-DOD-AWARDS-VYSNOVA-CONTRACT
, , , ,

Vysnova Awarded Task Order 3 Under The DSCA AM&E Support Services

DSCA-DOD-AWARDS-VYSNOVA-CONTRACT

Vysnova Awarded Task Order 3 (TO3) Under The DSCA AM&E Support Services

September 30, 2019:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order 3 (TO3) under the Defense Security Cooperation Agency (DSCA) Assessment, Monitoring, and Evaluation (AM&E) support services indefinite-delivery/indefinite-quantity (IDIQ) contract for Functional Category 3 (FC 3). Under TO3 Vysnova and DevTech Systems will provide a broad range of technical expertise to evaluate the effectiveness of a wide range of security cooperation missions and initiatives throughout the DoD, including planning and conducting evaluations. Specifically, TO3 will involve evaluations of US-led Institutional Capacity Building (ICB) programs in case study countries including Ukraine, Indonesia, and Colombia.
 
Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract
,

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Awarded TO 0709 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0709 (TO 0709) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0709 Vysnova will conduct active surveillance for high pathogenic and lethal strains of influenza A (H7N9) in high risk regions of Vietnam.

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract
, ,

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

Vysnova Partners Inc. Awarded TO 0738 Under NAMRU-2 SABER II IDIQ Contract

September 30, 2018:  Vysnova Partners Inc. (Vysnova) has been awarded Task Order N6264518F0738 (TO 0738) under the Navy Medical Unit 2 (NAMRU 2) Southeast Asia Biosurveillance and Epidemiology Research (SABER) II indefinite-delivery/indefinite-quantity (IDIQ) contract. Under TO 0738 Vysnova will provide an in-depth analysis for a clinical study evaluating the role of the candidate predictive biomarker, tryptase, for dengue fever security.